サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1421583

ファーマコゲノミクス技術市場、シェア、規模、動向、産業分析レポート：技術別、治療分野別、地域別およびセグメント動向、2023年～2032年

Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
ファーマコゲノミクス技術市場、シェア、規模、動向、産業分析レポート：技術別、治療分野別、地域別およびセグメント動向、2023年～2032年
出版日: 2023年11月23日
発行: Polaris Market Research
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のファーマコゲノミクス技術市場規模は2032年までに141億米ドルに達する見込みです。

この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

診断学の分野は、新しい生物学的療法のイントロダクションしばしば伴う、ファーマコゲノミクス検査の利用可能性の増加に適応するために、変革の最中にあります。これらの検査には、費用対効果の高い治療選択肢を提供するだけでなく、医薬品開発プロセスを強化するという二重のメリットがあります。

従来の方法に比べ、これらの検査の採用に伴う利点は大きいです。第一に、これらの検査は疾病リスクの予測を可能にし、特定の病態に罹りやすい個人を特定するのに役立ちます。第二に、これらの検査は患者の層別化を助け、ヘルスケア提供者が各患者の特定の遺伝的特徴に合わせた治療を行うことを可能にします。この個別化されたアプローチは、より効果的な治療と副作用の減少につながります。最後に、ファーマコゲノミクス検査は治療反応のモニタリングに役立ち、治療が軌道に乗っていることを確認し、必要に応じて調整を行うことができます。

ファーマコゲノミクス検査製品は、個々の患者の治療レジメンをカスタマイズし、最適化する上で、ヘルスケア専門家を支援する重要な役割を果たしています。ファーマコゲノミクスとセラノスティクスの領域は、統合医療の新たな道を開きつつあります。この専門的な分子診断検査のカテゴリーにおける急速な進歩は、リアルタイムの疾患治療の評価を積極的に強化し、患者ケアの改善につながります。

とはいえ、ファーマコゲノミクスに基づく検査を医薬品開発プロセスにタイムリーに組み込むことに関する課題もあり、これが同時承認の妨げになることもあります。特定の治療に対する反応の個人差や集団差を特定することを目的とした臨床試験の効果的なデザインと実施は、セラノスティクスの成功に不可欠な要素となっています。

ファーマコゲノミクス技術市場レポートハイライト

  • がんの発症が増加し、個別化治療、腫瘍プロファイリング、診断率の上昇に対するニーズが世界中で高まっていることから、予測期間中、がん分野が最も急成長すると予測されます。
  • 2022年には、PCRセグメントが最大の市場シェアを占めました。これは、セラノスティクスの著しい進歩があり、その高い効率と高スループットスクリーニングに関連する利点がエンドユーザーの間で採用されているためです。
  • 2022年には、北米が最大の市場シェアを占めました。これは、主要プレイヤーの存在、よく発達した業界大小プレイヤー、膨大な研究者プール、業界アカデミアの広範なネットワークによるものです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のファーマコゲノミクス技術市場に関する洞察

  • ファーマコゲノミクス技術市場- 業界スナップショット
  • ファーマコゲノミクス技術市場力学
    • 促進要因と機会
      • 個別化されたヘルスケアの意識と導入の向上
      • テクノロジーの進歩
    • 抑制要因と課題
      • 費用と払い戻し
  • PESTLE分析
  • ファーマコゲノミクス技術の業界動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界のファーマコゲノミクス技術市場：技術別

  • 主な調査結果
  • イントロダクション
  • PCR
  • 現場ハイブリダイゼーション
  • 免疫組織化学
  • シーケンス
  • その他

第6章 世界のファーマコゲノミクス技術市場：治療分野別

  • 主な調査結果
  • イントロダクション
  • 腫瘍学
  • 神経学的障害
  • 循環器疾患
  • 免疫疾患
  • 感染症
  • その他

第7章 世界のファーマコゲノミクス技術市場：地域別

  • 主な調査結果
  • イントロダクション
    • ファーマコゲノミクス技術市場評価、地域、2019-2032年
  • ファーマコゲノミクス技術市場-北米
    • 北米：ファーマコゲノミクス技術市場、治療領域別、2019-2032年
    • 北米：ファーマコゲノミクス技術市場、技術別、2019-2032年
    • ファーマコゲノミクス技術市場-米国
    • ファーマコゲノミクス技術市場- カナダ
  • ファーマコゲノミクス技術市場- 欧州
    • 欧州：ファーマコゲノミクス技術市場、治療領域別、2019-2032年
    • 欧州：ファーマコゲノミクス技術市場、技術別、2019-2032年
    • ファーマコゲノミクス技術市場- 英国
    • ファーマコゲノミクス技術市場- フランス
    • ファーマコゲノミクス技術市場- ドイツ
    • ファーマコゲノミクス技術市場- イタリア
    • ファーマコゲノミクス技術市場- スペイン
    • ファーマコゲノミクス技術市場- オランダ
    • ファーマコゲノミクス技術市場- ロシア
  • ファーマコゲノミクス技術市場- アジア太平洋
    • アジア太平洋：ファーマコゲノミクス技術市場、治療分野別、2019～2032年
    • アジア太平洋：ファーマコゲノミクス技術市場、技術別、2019-2032年
    • ファーマコゲノミクス技術市場- 中国
    • ファーマコゲノミクス技術市場- インド
    • ファーマコゲノミクス技術市場- マレーシア
    • ファーマコゲノミクス技術市場- 日本
    • ファーマコゲノミクス技術市場- インドネシア
    • ファーマコゲノミクス技術市場- 韓国
  • ファーマコゲノミクス技術市場-中東およびアフリカ
    • 中東およびアフリカ：ファーマコゲノミクス技術市場、治療分野別、2019-2032年
    • 中東およびアフリカ：ファーマコゲノミクス技術市場、技術別、2019-2032年
    • ファーマコゲノミクス技術市場- サウジアラビア
    • ファーマコゲノミクス技術市場- アラブ首長国連邦
    • ファーマコゲノミクス技術市場- イスラエル
    • ファーマコゲノミクス技術市場- 南アフリカ
  • ファーマコゲノミクス技術市場-ラテンアメリカ
    • ラテンアメリカ：ファーマコゲノミクス技術市場、治療分野別、2019-2032年
    • ラテンアメリカ：ファーマコゲノミクス技術市場、技術別、2019-2032年
    • ファーマコゲノミクス技術市場- メキシコ
    • ファーマコゲノミクス技術市場- ブラジル
    • ファーマコゲノミクス技術市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GE HealthCare
  • Illumina, Inc
  • Leica Biosystems Nussloch GmBH
  • MDPI
  • Pfizer Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc
図表

List of Tables

  • Table 1 Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 2 Global Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 3 Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 5 North America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 6 U.S.: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 7 U.S.: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 8 Canada: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 9 Canada: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 10 Europe: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 11 Europe: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 12 UK: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 13 UK: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 14 France: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 15 France: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 16 Germany: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 17 Germany: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 18 Italy: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 19 Italy: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 20 Spain: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 21 Spain: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 24 Russia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 25 Russia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 28 China: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 29 China: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 30 India: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 31 India: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 34 Japan: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 35 Japan: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 38 South Korea: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 39 South Korea: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 44 UAE: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 45 UAE: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 46 Israel: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 47 Israel: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 48 South Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 49 South Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 50 Latin America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 51 Latin America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 52 Mexico: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 53 Mexico: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 54 Brazil: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 55 Brazil: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • Table 56 Argentina: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • Table 57 Argentina: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Pharmacogenomics Technologies Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Therapeutic Area
  • Figure 7 Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Technology
  • Figure 9 Global Pharmacogenomics Technologies Market, by Technology, 2022 & 2032 (USD Billion)
  • Figure 10 Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Pharmacogenomics Technologies Market
目次
Product Code: PM3906

The global pharmacogenomics technologies market size is expected to reach USD 14.10 billion by 2032, according to a new study by Polaris Market Research.

The report "Pharmacogenomics Technologies Market Share, Size, Trends, Industry Analysis Report, By Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others); By Therapeutic Area; By Region; And Segment Forecasts, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The field of diagnostics is undergoing a transformation as it adapts to the increasing availability of pharmacogenomic tests, often accompanying the introduction of new biological therapies. These tests have the dual benefit of not only providing cost-effective treatment options but also enhancing the drug development process.

The advantages associated with the adoption of these tests over traditional methods are substantial. First, they enable the prediction of disease risks, helping identify individuals who are more susceptible to certain conditions. Second, these tests aid in patient stratification, allowing healthcare providers to tailor treatments to the specific genetic characteristics of each patient. This personalized approach leads to more effective therapies and fewer adverse effects. Finally, pharmacogenomic tests are instrumental in monitoring therapeutic responses, ensuring that treatments are on track and adjustments can be made when necessary.

Pharmacogenomics testing products play a crucial role in assisting healthcare professionals in customizing and optimizing the therapeutic regimens for individual patients. The realms of pharmacogenomics and theranostics are opening new avenues for integrated medicine. The rapid advancements within this specialized category of molecular diagnostic tests are actively enhancing the assessment of real-time disease treatment, leading to improvements in patient care.

Nevertheless, there are challenges related to the timely integration of pharmacogenomic-based testing into drug development processes, which can hinder simultaneous approval. The effective design and execution of clinical trials aimed at identifying individual and population variations in response to a particular therapy have become essential factors for the success of theranostics.

Pharmacogenomics Technologies Market Report Highlights

  • The oncology segment is expected to witness the fastest growth during the forecast period, as there is growing onset of cancer, increasing need for personalized treatment, tumor profiling, rise in diagnosis rate, across the globe.
  • In 2022, PCR segment held the largest market share, as there are significant advancements in theranostics, advantages associated with its higher efficiency and high throughput screening coupled with adoption among end users.
  • In 2022, North America held the largest market share, owing to presence of key players, well developed industry big and small players, huge pool of researchers, and extensive network of industry academia.
  • The key market players include QIAGEN, GE HealthCare, Agilent Technologies, Roche, Foundation Medicine, Thermo Fisher Scientific., Leica Biosystems, and Pfizer.

Polaris Market Research has segmented the pharmacogenomics technologies market report based on technology, therapeutic area, and region:

Pharmacogenomics Technologies, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

  • PCR
  • In-situ Hybridization
  • Immunohistochemistry
  • Sequencing
  • Others

Pharmacogenomics Technologies, Therapeutic Area Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others

Pharmacogenomics Technologies, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pharmacogenomics Technologies Market Insights

  • 4.1. Pharmacogenomics Technologies Market - Industry Snapshot
  • 4.2. Pharmacogenomics Technologies Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Awareness and Adoption of Personalized Healthcare
      • 4.2.1.2. Advancements in Technology
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Costs and Reimbursement
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Pharmacogenomics Technologies Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pharmacogenomics Technologies Market, by Technology

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pharmacogenomics Technologies, by Technology, 2019-2032 (USD Billion)
  • 5.3. PCR
    • 5.3.1. Global Pharmacogenomics Technologies Market, by PCR, by Region, 2019-2032 (USD Billion)
  • 5.4. In-situ Hybridization
    • 5.4.1. Global Pharmacogenomics Technologies Market, by In-situ Hybridization, by Region, 2019-2032 (USD Billion)
  • 5.5. Immunohistochemistry
    • 5.5.1. Global Pharmacogenomics Technologies Market, by Immunohistochemistry, by Region, 2019-2032 (USD Billion)
  • 5.6. Sequencing
    • 5.6.1. Global Pharmacogenomics Technologies Market, by Sequencing, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Pharmacogenomics Technologies Market, by Therapeutic Area

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 6.3. Oncology
    • 6.3.1. Global Pharmacogenomics Technologies Market, by Oncology, by Region, 2019-2032 (USD Billion)
    • 6.3.2. Lung Cancer
      • 6.3.2.1. Global Pharmacogenomics Technologies Market, by Lung Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.3. Breast Cancer
      • 6.3.3.1. Global Pharmacogenomics Technologies Market, by Breast Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.4. Colorectal Cancer
      • 6.3.4.1. Global Pharmacogenomics Technologies Market, by Colorectal Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.5. Cervical Cancer
      • 6.3.5.1. Global Pharmacogenomics Technologies Market, by Cervical Cancer, by Region, 2019-2032 (USD Billion)
    • 6.3.6. Others
      • 6.3.6.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)
  • 6.4. Neurological Disorders
    • 6.4.1. Global Pharmacogenomics Technologies Market, by Neurological Disorders, by Region, 2019-2032 (USD Billion)
  • 6.5. Cardiovascular Disease
    • 6.5.1. Global Pharmacogenomics Technologies Market, by Cardiovascular Disease, by Region, 2019-2032 (USD Billion)
  • 6.6. Immunological Disorders
    • 6.6.1. Global Pharmacogenomics Technologies Market, by Immunological Disorders, by Region, 2019-2032 (USD Billion)
  • 6.7. Infectious Diseases
    • 6.7.1. Global Pharmacogenomics Technologies Market, by Infectious Diseases, by Region, 2019-2032 (USD Billion)
  • 6.8. Others
    • 6.8.1. Global Pharmacogenomics Technologies Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Pharmacogenomics Technologies Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Pharmacogenomics Technologies Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Pharmacogenomics Technologies Market - North America
    • 7.3.1. North America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.3.2. North America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.3.3. Pharmacogenomics Technologies Market - U.S.
      • 7.3.3.1. U.S.: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.3.4. Pharmacogenomics Technologies Market - Canada
      • 7.3.4.1. Canada: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.4. Pharmacogenomics Technologies Market - Europe
    • 7.4.1. Europe: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.3. Pharmacogenomics Technologies Market - UK
      • 7.4.3.1. UK: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.4. Pharmacogenomics Technologies Market - France
      • 7.4.4.1. France: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.5. Pharmacogenomics Technologies Market - Germany
      • 7.4.5.1. Germany: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.6. Pharmacogenomics Technologies Market - Italy
      • 7.4.6.1. Italy: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.7. Pharmacogenomics Technologies Market - Spain
      • 7.4.7.1. Spain: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.8. Pharmacogenomics Technologies Market - Netherlands
      • 7.4.8.1. Netherlands: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.4.9. Pharmacogenomics Technologies Market - Russia
      • 7.4.9.1. Russia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.5. Pharmacogenomics Technologies Market - Asia Pacific
    • 7.5.1. Asia Pacific: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.3. Pharmacogenomics Technologies Market - China
      • 7.5.3.1. China: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.4. Pharmacogenomics Technologies Market - India
      • 7.5.4.1. India: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.5. Pharmacogenomics Technologies Market - Malaysia
      • 7.5.5.1. Malaysia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.6. Pharmacogenomics Technologies Market - Japan
      • 7.5.6.1. Japan: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.7. Pharmacogenomics Technologies Market - Indonesia
      • 7.5.7.1. Indonesia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.5.8. Pharmacogenomics Technologies Market - South Korea
      • 7.5.8.1. South Korea: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.6. Pharmacogenomics Technologies Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.3. Pharmacogenomics Technologies Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.4. Pharmacogenomics Technologies Market - UAE
      • 7.6.4.1. UAE: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.5. Pharmacogenomics Technologies Market - Israel
      • 7.6.5.1. Israel: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.6.6. Pharmacogenomics Technologies Market - South Africa
      • 7.6.6.1. South Africa: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
  • 7.7. Pharmacogenomics Technologies Market - Latin America
    • 7.7.1. Latin America: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.3. Pharmacogenomics Technologies Market - Mexico
      • 7.7.3.1. Mexico: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.4. Pharmacogenomics Technologies Market - Brazil
      • 7.7.4.1. Brazil: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)
    • 7.7.5. Pharmacogenomics Technologies Market - Argentina
      • 7.7.5.1. Argentina: Pharmacogenomics Technologies Market, by Therapeutic Area, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Pharmacogenomics Technologies Market, by Technology, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Agilent Technologies, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. F. Hoffmann-La Roche Ltd
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Foundation Medicine, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GE HealthCare
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Illumina, Inc
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Leica Biosystems Nussloch GmBH
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. MDPI
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Pfizer Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. QIAGEN
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Thermo Fisher Scientific Inc
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development